XVIVO Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Xvivo Perfusion (STO: XVIVO)
›
Xvivo Perfusion (STO: XVIVO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 207 employees.
The shares were at 195.90 SEK on 19 November 2026, up 15.2% over 52 weeks. Its 52-week range is 160.10 SEK to 314.80 SEK: the price is 37.8% below the high and 22.4% above the low.
At a market capitalisation of 6.17B SEK, it trades at 47.3 times trailing earnings and 33.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 85% for XVIVO.
Xvivo Perfusion reports return on equity of 1.2%, an operating margin of 13.3% and revenue up 33.5% year over year.
It holds more cash than debt, a net cash position of 192.63M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 304.00 SEK is 55.2% above the current price. The next earnings report is expected on 28 January 2027.